StreetInsider.com News Articles

Form 4 Veraxa Biotech AG - Post For: Oct 20 Filed by: Ziegler Christoph Samuel

Wed, 21 Oct 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20261021/27216515.html

Form 6-K Veraxa Biotech AG - Post For: Oct 15

Thu, 15 Oct 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20261015/27193471.html

VERAXA Biotech Presents in vivo Proof-of-Concept Data for BiTAC®-ADC Technology at World ADC Congress

Tue, 13 Oct 2026 07:00:00 -0400

In vivo data confirm activation of prodrug payload inside tumor cells following systemic administration of BiTAC-ADC molecules leading to potent anti-tumor activity

ZURICH, SWITZERLAND – October 13, 2026 -- VERAXA Biotech AG (NASDAQ: VRXA; “VERAXA”), an emerging leader in designing novel cancer therapies, today presented first in vivo proof-of-concept data and additional in vitro data validating its novel BiTAC-ADC technology platform at the 17^th World ADC Congress in San Diego, CA, USA. The in vivo data demonstrate that a systemically applied, single dose of the two-component BiTAC-ADC selectively triggered a tumor-specific response resulting in a significant reduction in tumor volume,

VERAXA Biotech Presents in vivo Proof-of-Concept Data for BiTAC®-ADC Technology at World ADC Congress

Tue, 13 Oct 2026 07:00:00 -0400

In vivo data confirm activation of prodrug payload inside tumor cells following systemic administration of BiTAC-ADC molecules leading to potent anti-tumor activity

Veraxa Biotech stock gains on FDA-aligned testing strategy

Wed, 07 Oct 2026 09:12:18 -0400

Investing.com -- Veraxa Biotech AG (NASDAQ:VRXA) shares rose 3.7% in premarket trading Wednesday following the company's announcement of a strategy to implement FDA-aligned New Approach Methodologies across its preclinical programs.

The antibody-based cancer therapy developer said the approach could enable faster clinical advancement while significantly reducing animal testing. The strategy positions the company ahead of the FDA's 2025 roadmap, which encourages phased reduction of animal testing in favor of human-relevant, non-animal test methods.

New Approach Methodologies include cell-based assays, organ-on-chip systems, computational modeling and ex vivo tissue models designed to predict human biological responses while reducing dependence on animal

Veraxa Biotech stock gains on FDA-aligned testing strategy

Wed, 07 Oct 2026 09:12:18 -0400

Veraxa Biotech outlines FDA-aligned animal testing reduction strategy

Wed, 07 Oct 2026 07:01:40 -0400

VERAXA Biotech AG (NASDAQ: VRXA) provided an update on its implementation of New Approach Methodologies (NAMs) across its preclinical research and development programs, according to a company statement dated Oct. 7, 2026.

NAMs include cell-based assays, organ-on-chip systems, computational modeling, and ex vivo tissue models. The FDA's 2025 roadmap encourages phased reduction and eventual replacement of animal testing with human-relevant, non-animal test methods. VERAXA said the shift could reduce development costs and timelines by bypassing certain non-human primate toxicology studies.

"We see NAMs as not just a regulatory obligation, but also as a scientific opportunity," said Christoph Erkel, Ph.D., Chief Scientific Officer

VERAXA Biotech Provides Overview on Implementation of FDA-Aligned Human-Relevant Models into R&D Strategy

Wed, 07 Oct 2026 07:00:00 -0400

Consistent Use of New Approach Methodologies (NAMs) to Potentially Accelerate BiTAC® Oncology Pipeline and Significantly Reduce Animal Testing Needs

ZURICH, SWITZERLAND, Oct. 07, 2026 (GLOBE NEWSWIRE) -- VERAXA Biotech AG (NASDAQ: VRXA; “VERAXA” or the “Company”), a leading developer of next-generation antibody-based cancer therapies, today provided an update on its strategy and progress to implement a suite of U.S. Food and Drug Administration (FDA) aligned New Approach Methodologies (NAMs) across its preclinical research and development programs, potentially enabling faster clinical advancement while significantly reducing animal testing. This strategic implementation positions VERAXA ahead of the FDA’s

VERAXA Biotech Provides Overview on Implementation of FDA-Aligned Human-Relevant Models into R&D Strategy

Wed, 07 Oct 2026 07:00:00 -0400

Consistent Use of New Approach Methodologies (NAMs) to Potentially Accelerate BiTAC® Oncology Pipeline and Significantly Reduce Animal Testing Needs

VERAXA Biotech Provides Overview on Implementation of FDA-Aligned Human-Relevant Models into R&D Strategy

Wed, 07 Oct 2026 07:00:00 -0400

VERAXA Biotech Provides Overview on Implementation of FDA-Aligned Human-Relevant Models into R&D Strategy

Wed, 07 Oct 2026 07:00:00 -0400

Form 4 Veraxa Biotech AG For: Sep 10 Filed by: Hosseinion Warren

Tue, 29 Sep 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260929/27122583.html

Form 3 Veraxa Biotech AG - Post For: Sep 01 Filed by: Willener Raju Sudir

Tue, 22 Sep 2026 17:10:00 -0400

si-local-file:///var/storage/secattach/20260922/27091838.html

Form 3 Veraxa Biotech AG - Post For: Sep 01 Filed by: Willener Raju Sudir

Mon, 14 Sep 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260914/27058489.html

Veraxa Biotech names Raju Willener as CFO

Fri, 04 Sep 2026 07:00:27 -0400

VERAXA Biotech AG (NASDAQ: VRXA) has appointed Raju Willener as Chief Financial Officer, effective immediately, according to a company press release. He replaces Carl von Halem in the role and will report to CEO and Co-Founder Christoph Antz, Ph.D.

Willener brings more than three decades of experience in investment banking, corporate finance, asset management and capital markets, with senior roles held across the U.S., Europe and Asia. He previously oversaw investment portfolios exceeding CHF 30 billion in assets under management at global financial institutions.

Most recently, Willener served as Director of Corporate Development at Exentis Group AG before being appointed CFO of

VERAXA Biotech Appoints Raju Willener as Chief Financial Officer

Fri, 04 Sep 2026 07:00:00 -0400

Mr. Willener brings more than three decades of global capital markets and corporate finance experience to support advancement of the Company’s pipeline of potential best-in-class therapies led by its BiTAC® platform

Zurich, Switzerland, Sept. 04, 2026 (GLOBE NEWSWIRE) -- VERAXA Biotech AG (NASDAQ: VRXA; “VERAXA” or the “Company”), a leading developer of next-generation antibody-based cancer therapies, today announced the appointment of Raju Willener as Chief Financial Officer (CFO), effective immediately. Mr. Willener will report to Christoph Antz, Ph.D., Chief Executive Officer and Co-Founder. Mr. Willener brings more than three decades of financial leadership across global capital markets and

VERAXA Biotech Appoints Raju Willener as Chief Financial Officer

Fri, 04 Sep 2026 07:00:00 -0400

Form 6-K Veraxa Biotech AG - Post For: Aug 24

Mon, 24 Aug 2026 07:39:00 -0400

si-local-file:///var/storage/secattach/20260824/26964280.html

Form 6-K Veraxa Biotech AG - Post For: Aug 24

Mon, 24 Aug 2026 07:39:00 -0400

si-local-file:///var/storage/secattach/20260824/26964280.html

Veraxa Biotech and Secarna report early AOC research milestone

Mon, 24 Aug 2026 07:01:46 -0400

Veraxa Biotech AG (NASDAQ: VRXA) and Secarna Pharmaceuticals GmbH & Co. KG announced initial positive results from their joint research collaboration to develop antibody oligonucleotide conjugates (AOCs) for the treatment of autoimmune and chronic immune diseases, according to a press release.

In early in vitro studies, an AOC candidate produced by combining both companies' technologies showed greater potency compared to an equivalent unconjugated oligonucleotide. The companies said they are now discussing next steps in the alliance, which was established less than a year ago.

Christoph Erkel, Ph.D., Chief Scientific Officer of Veraxa, said the milestone "demonstrates that our conjugation technology powered by

Veraxa Biotech and Secarna report early AOC research milestone

Mon, 24 Aug 2026 07:01:46 -0400

Christoph Erkel, Ph.D., Chief Scientific Officer of Veraxa, said the milestone "demonstrates that our conjugation technology powered by

VERAXA Biotech and Secarna Pharmaceuticals Achieve Research Milestone in Antibody Oligonucleotide Conjugate (AOC) Alliance

Mon, 24 Aug 2026 07:00:00 -0400

Successful in vitro proof-of-concept study demonstrates the potential to create novel antibody-oligonucleotide conjugates (AOCs) by combining both parties’ technologies and expertise

ZURICH, SWITZERLAND, and MARTINSRIED/MUNICH, GERMANY, Aug. 24, 2026 (GLOBE NEWSWIRE) -- VERAXA Biotech AG (NASDAQ: VRXA; “VERAXA”), an emerging leader in the design and development of next-generation cancer therapeutics, and Secarna Pharmaceuticals GmbH & Co. KG (“Secarna”), a company redefining the discovery and development of best-in-class oligonucleotide therapeutics, today announced initial positive results from their strategic research collaboration to develop next-generation antibody oligonucleotide conjugates (AOCs) for the treatment of autoimmune and chronic immune diseases.

VERAXA Biotech and Secarna Pharmaceuticals Achieve Research Milestone in Antibody Oligonucleotide Conjugate (AOC) Alliance

Mon, 24 Aug 2026 07:00:00 -0400

Successful in vitro proof-of-concept study demonstrates the potential to create novel antibody-oligonucleotide conjugates (AOCs) by combining both parties’ technologies and expertise

Form 3 Veraxa Biotech AG - Post For: Jul 10 Filed by: von Halem Carl

Thu, 20 Aug 2026 16:00:00 -0400

si-local-file:///var/storage/secattach/20260820/26956034.html

Form 3 Veraxa Biotech AG - Post For: Jul 10 Filed by: von Halem Carl

Thu, 20 Aug 2026 16:00:00 -0400

si-local-file:///var/storage/secattach/20260820/26956034.html